Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Authors

Hiddo J L Heerspink, University of Groningen
Janet B McGill, Washington University School of Medicine in St. Louis
et al.

Journal

Diabetes Research and Clinical Practice

Publication Date

10-1-2023

Volume

204

First Page

110908

Document Type

Open Access Publication

DOI

10.1016/j.diabres.2023.110908

Rights and Permissions

Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, Groop PH, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Scott C, Edfors R, Scheerer MF, Kolkhof P, McGill JB. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Heerspink, Hiddo J L; McGill, Janet B; and et al., "Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial." Diabetes Research and Clinical Practice. 204, 110908 (2023).
https://digitalcommons.wustl.edu/oa_4/3093

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.